RETROSPECTIVE

The Adipose-derived Stem Cell: Looking Back and Looking Ahead

Patricia A. Zuk

Regenerative Bioengineering and Repair Laboratory, Department of Surgery, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095

Submitted January 4, 2010; Revised March 29, 2010; Accepted March 31, 2010
Monitoring Editor: Doug Kellogg

In 2002, researchers at UCLA published a manuscript in *Molecular Biology of the Cell* describing a novel adult stem cell population isolated from adipose tissue—the adipose-derived stem cell (ASC). Since that time, the ASC has gone on to be one of the most popular adult stem cell populations currently being used in the stem cell field. With multilineage mesodermal potential and possible ectodermal and endodermal potentials also, the ASC could conceivably be an alternate to pluripotent ES cells in both the lab and in the clinic. In this retrospective article, a historical perspective on the ASC is given together with exciting new applications for the stem cell being considered today.

Over the last 10 years, giant strides have been made worldwide in the adult stem cell field. It seemed every month another groundbreaking article was being published describing a unique adult stem cell population from a tissue we never could have imagined. Skin, liver, digestive epithelium, dental pulp, hair follicles—even amniotic fluid appeared to be a stem cell source that could be manipulated in the laboratory in wonderful ways. However, at the start of the decade, the number of adult stem cells being studied seemed to be limited to a few, but in 2002, our team at UCLA had the privilege of being able to add to the adult stem cell roster with the publication of a manuscript in *Molecular Biology of the Cell* (Zuk et al., 2002) that characterized a stem cell population from human adipose tissue. Since then it seems that the adult stem cell field has “taken off” into new and exciting territories.

ADULT STEM CELLS AND THE ASC: A BRIEF HISTORY

At its heart there are essentially only two categories of stem cells: the embryonic stem cell (ES cell) and the postnatal stem cell (i.e., adult stem cell). The ES cell, as its name implies, is derived from the embryo—more specifically, from the blastocyst’s inner cell mass. The adult stem cell, in contrast, is derived from postnatal tissues and can include fat-derived derived stem cells and umbilical cord blood stem cells.

Despite the impression given to most people by the mainstream media, the adult stem cell field isn’t a recent development. In fact, the origins of the field can be traced back to the laboratory of Ernest McCulloch and James Till at the Ontario Cancer Institute in Toronto. In two groundbreaking articles published in 1963, McCulloch and Till, with Andy Becker and Lou Siminovitch, reported on the presence of self-renewing cells within the bone marrow of mice and postulated that these cells were regenerative stem cells (Becker et al., 1963; Zhang et al., 1999). Of course, we now know these cells to be hematopoietic stem cells (HSCs), the first described adult stem cell, although one could argue for the muscle-derived satellite cell described in 1961 to take this title (Mauro, 1961; Moss and Leblond, 1971). From the work of McCulloch and Till, the adult stem cell field gathered momentum in the late sixties and early seventies as patients suffering from SCID (severe combined immunodeficiency) were treated using bone marrow transplants or HSC concentrates (Dicke and van Bekkum, 1973; Lin et al., 2000). In 1978, HSCs were identified in umbilical cord blood and a new population of adult stem cells was born: the umbilical cord blood stem cell (Emerson et al., 1985; Broxmeyer et al., 1990). The late 1960s also saw the introduction of the bone marrow mesenchymal stem cell (MSC; Friedenstein et al., 1968). Finally, in 1992, the adult stem cell list grew again with the work of Reynolds and Weiss (1992), who described neural stem cells isolated from murine striatal tissue.

Until the year 2000, adult stem cell articles seemed to be limited to the HSC, the MSC, the NSC (neural stem cell) and the muscle satellite cell. However, 2001 saw the addition of another adult stem cell to the roster: the adipose-derived stem cell (ASC). In the journal *Tissue Engineering* our team first used the term processed lipoaspirate (PLA) cells, owing to their isolation from human lipoaspirates, and proposed that the ASC was a multilineage stem cell population that could be isolated from the stromal-vascular fraction of adipose tissue (Zuk et al., 2001). Why adipose tissue would contain a stem cell population is not that far-fetched. The conversion of adipose tissue to calcified bone has been observed in several diseases including lupus, subcutaneous fat necrosis (Shackelford et al., 1975) and Paget’s disease (Clarke and Williams, 1975). This conversion should not be possible by the resident, unipotent preadipocyte precursor population. Also, adipose tissue is derived from the embryologic
mesenchyme and possesses a well-described stroma that like bone marrow could feasibly contain a mesenchymal stem cell population. The initial results published in *Tissue Engineering* seemed to support this theory.

To confirm this theory, our team undertook a more extensive molecular and biochemical analysis of the ASC (i.e., the PLA cell) in our 2002 *MBoC* article (Zuk et al., 2002). This article not only confirmed our earlier work that the ASC is capable of differentiating into multiple mesodermal cell types—adipogenic, chondrogenic, osteogenic, and myogenic (Zuk et al., 2001), but utilized additional approaches such as the expression of multiple lineage-specific genes and functional biochemical assays to confirm this property. Combining these approaches, the data of our *MBoC* article appeared to fulfill one important requirement of a stem cell: differentiation capacity. However, the *MBoC* article also fulfilled another important requirement specific to adult stem cells, that of clonogenicity. One of the most obvious hurdles for adult stem cell identification is the heterogeneity of their origin tissue. Because of this, the observed multilineage differentiation by ASCs may simply be due to the presence of multiple precursor populations, each completing their development. One way to circumvent this would be the isolation of a stem cell, combined with proof of its multipotency. Therefore, the 2002 *MBoC* article also contained data confirming multilineage differentiation of single ASC clones.

Having demonstrated differentiation capacity and clonogenicity, we felt confident that the ASC was, in fact, a new adult stem cell population and, since 2002, many groups have confirmed our proposal in both human and animal ASC populations. The ability of both human and animal ASCs to undergo mesodermal differentiation at the in vivo level has also been presented using a wide variety of animal model systems, but what has become more exciting is the potential of ASCs beyond the mesodermal lineage. Our original *MBoC* article suggested that ASCs might possess the ability to differentiate to neuronal-like cells of the ectodermal lineage. Confirmatory studies examining this capacity quickly followed (Safford et al., 2002; Ashjian, 2003). Today, the ability of ASCs to form cells consistent with neurons (Kang et al., 2004), oligodendrocytes (Safford et al., 2004), functional Schwann cells (Kingham et al., 2007; Xu et al., 2008), and cells of the epidermal lineage (Trottier et al., 2008) have added credence to the theory that ASCs may be pluripotent rather than multipotent. Not surprisingly, studies describing the endodermal differentiation of ASCs have also appeared, with ASCs being induced to form hepatocytes and pancreatic islets (Seo et al., 2005; Timper et al., 2006).

### Table 1. Current application of ASCs: a summary

| ASC research activity                  | References                          |
|----------------------------------------|-------------------------------------|
| Adipose tissue                         | Mauney et al., 2007                 |
| Bone tissue                            | Cowan et al., 2004; Dudas et al., 2006; Yoon et al., 2007 |
| Cartilage                              |                                      |
| Skeletal muscle                        | Bacou et al., 2004; Goudenege et al., 2009 |
| Smooth muscle                          | Rodriguez et al., 2006              |
| Neural                                 | Ashjian, 2003; Safford et al., 2004; Erba et al., 2009; Nakada et al., 2009 |
| Vocal fold/laryngeal tissue            | Kumai et al., 2009; Long et al., 2009 |
| Bladder/urethra                        | Jack et al., 2005                   |
| Cardiovascular tissue/vascular tissue  | Miranville et al., 2004; Heydarpour-Hagvall et al., 2008; Froehlich et al., 2009; Okura et al., 2009c |
| Hematopoietic                          | Cousin, 2003; Puissant et al., 2005 |
| Pancreatic tissue/islet development    | Timper et al., 2006; Okura et al., 2009a; Kaijousaka et al., 2010 |
| Hepatic tissue                         | Seo et al., 2005; Banas et al., 2007; Okura et al., 2009b |
| Epithelial/skin tissue                 | Brzoska et al., 2005; Jeong, 2009   |
| Kidney tubule epithelial cell          | Li et al., 2009                      |
| ASCs in disease and injury             |                                      |
| Intervertebral disc repair             | Heu et al., 2008                     |
| Spinal cord injury                     | Ryu et al., 2009                     |
| Peripheral nerve regeneration          | di Summa et al., 2009                |
| Glioblastoma treatment                 | Josiah et al., 2010                  |
| Huntington's                           | Lee et al., 2009                     |
| Multiple sclerosis                     | Riordan et al., 2009                 |
| Stroke                                 | Lin et al., 2010                     |
| Urinary incontinence                   | Lin et al., 2009                      |
| Erectile dysfunction                   | Liang et al., 2009                   |
| Liver repair                           | Lin et al., 2009b                    |
| Diabetes                               | Gonzalez-Rey et al., 2009            |
| Colitis                                | Kondo et al., 2009                   |
| Ischemia                               | Gonzalez-Rey et al., 2010            |
| Rheumatoid arthritis                   | Park et al., 2008                    |
| Antiaging                              | Trottier et al., 2008                |
| Wound healing/skin regeneration        | Conejero et al., 2006                |
| Cleft palate                           | Uysal and Mizuno, 2009               |
| ASC human trials                       |                                      |
| Calvarial defect                       | Lendeckel et al., 2004               |
| Crohn's disease                        | Garcia-Olmo et al., 2009; Taxonera et al., 2009 |
| Urinary incontinence                   | Yamamoto et al., 2009                |
| Graft vs. host disease                  | Fang et al., 2007                    |

References

- Kang et al., 2004
- Safford et al., 2002; Ashjian, 2003
- Gonzalez-Rey et al., 2009
- Kondo et al., 2009
- Gonzalez-Rey et al., 2010
- Park et al., 2008
- Trottier et al., 2008
- Conejero et al., 2006
- Uysal and Mizuno, 2009
theory that ASCs, like ES cells, may be pluripotent and capable of forming multiple cell types within all three germ layers was proposed.

THE WIDE, WIDE WORLD OF ASCs

The possibility that the ASC is pluripotent would obviously revolutionize the stem cell field. Why bother with the ethical and political difficulties of the ES cell when a plentiful source of similarly potent stem cells could be found in your fat? However, we have a long way to go with the ASC before such a statement should be seriously considered. Fortunately, researchers around the world consider the ASC exciting enough to make it the focus of their work. Today, a search of PubMed using the terms “adipose” and “stem cell” yields over 2000 entries, making the ASC one of the most popular adult stem cells currently being explored today.

Today, the proposed uses for ASCs in tissue repair/regeneration are quite impressive. Hot areas of research include ischemia revascularization, cardiovascular tissue regeneration, bone/cartilage repair, and urinary tract reconstruction (Table 1). With its mesodermal origin, the application of ASCs to bone and cartilage defects is obvious along with their use in tendon and intervertebral disk repair (Table 1). However, the use of ASCs is expanding to both the ectodermal and endodermal lineages. Work by di Summa et al. (2009) has suggested that rat ASCs may stimulate peripheral nerve repair, whereas Ryu et al. (2009) has observed functional recovery upon their transplantation into dogs with acute spinal cord damage. Liver injury repair may also be possible with transplantation of rat ASCs, decreasing key liver enzyme levels and increasing serum albumin (Liang et al., 2009). Even diabetes may be a target for ASC therapy, with murine ASCs reducing hyperglycemia in diabetic mice (Kajiyama et al., 2010). Most recently, researchers have begun to explore the potential uses of “reprogrammed” ASCs as IPS (induced pluripotent stem) cells and have suggested that the ASC may be easier to reprogram than the fibroblast (Sun et al., 2009).

However, researchers are also beginning to “think outside the box.” The transplantation of human ASCs into a murine model of Huntington’s appears to slow progression of the disease, inducing the expression of neuroprotective genes by the host (Lee et al., 2009). Human ASCs have recently been used to deliver myxoma virus to experimental gliomas in nude mice, making the ASC a possible vector for oncolytic viral treatment of brain tumors (Josiah et al., 2009). Human ASCs engineered to convert 5-fluorocytosine to the antitumor drug 5-fluorouracil have also been used to inhibit prostatic tumor growth. Finally, the ability of ASCs to suppress specific aspects of the immune system (Puissant et al., 2005) has created another exciting research avenue encompassing everything from organ antirejection to the amelioration of autoimmune diseases (Gonzalez et al., 2009; Riordan et al., 2009). Nothing seems to be out of the realm of possibility, with work by Park and colleagues investigating whether the secretory products from ASCs can act as antiwrinkle agents, promoting dermal thickness (Kim et al., 2009). Even the popular topic of erectile dysfunction may be solved with the transplantation of ASCs (Lin et al., 2009a).

What might be more exciting is the application of ASC in our clinics. Although the excitement regarding the ES cell has picked up with the Obama administration’s approving an increase in the number of new ES lines and a limited human clinical trial, what many people don’t realize is that the ES cell has yet to treat any disease. This in contrast to the HSC, which has been utilized successfully in medicine for the last four decades! On the basis of this, many researchers firmly believe that the adult stem cell might be more useful clinically useful than the ES cell. In support of this, there are emerging clinical applications of the ASC, which started in 2004 with the combination of ASCs and bone grafts to treat extensive craniofacial damage in a 7-year-old girl (Lendeckel et al., 2004) to a recently completed stage II clinical trial for Crohn’s disease (Garcia-Olmo et al., 2009). ASCs have also been applied in trials for urinary incontinence (Yamamoto et al., 2009) and graft versus host disease (Fang et al., 2007).

THE FUTURE OF ASCs

Looking back, the isolation of the ASC seemed to preface a decade that could easily be named the “decade of the adult stem cell,” with an impressive number of groundbreaking articles describing the isolation of adult stem cells not only from adipose tissue but from skin, liver, digestive epithelium, pancreas, and neural crest. Even tissues as unexpected as amniotic fluid, dental pulp, hair follicles, and eyelids have all been found to contain resident stem cell populations. However, the ASC does have one important advantage over these other sources—availability. There is no human tissue as expendable as adipose tissue, making it relatively easy to isolate adequate numbers of ASCs for possible human therapies. With this fact, together with the early clinical uses of ASCs that report no adverse effects, it would seem only a matter of time before more and more current applications of ASCs are reported. Although the ES cell with its proven self-renewal capacity and pluripotency would seem to be a more appropriate stem cell to use clinically, the recent work on ASCs would suggest that this adult stem cell may prove to be an equally powerful weapon in the treatment of human disease and injury. Only time will tell.

REFERENCES

Ashjian, P. H., Elbarbary, A. S., Edmonds, B., DeUpigarte, D. A., Zhu, M., Zuk, P. A., Lorenz, H. P., Benhaim, P., and Hedrick, M. H. (2003). In vitro differentiation of human processed lipoaspirate cells into early neural progenitors. Plast. Reconstr. Surg. 111, 1922–1931.

Bacou, F., el Andalousi, R. B., Daussin, P. A., Micallef, J. P., Levin, J. M., Chammas, M., Castella, L., Reyne, Y., and Neugues, J. (2004). Transplantation of adipose tissue-derived stromal cells increases mass and functional capacity of damaged skeletal muscle. Cell Transplant. 13, 103–111.

Banaz, A., Teratani, T., Yamamoto, Y., Tokuhara, M., Takeshita, F., Quinn, G., Okochi, H., and Ochiya, T. (2007). Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepatology 46, 219–228.

Becker, A. J., McCulloch, E. A., and Till, J. E. (1963). Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 197, 452–454.

Bromsmyer, H. E., Gluckman, E., Auerbach, A., Douglas, G. W., Friedman, H., Cooper, S., Hangoc, G., Kurtzberg, J., Bard, J., and Boyse, E. A. (1990). Human umbilical cord blood: a clinically useful source of transplantable hematopoietic stem/progenitor cells. Int. J. Cell Cloning 8(suppl 1), 76–89; discussion 89–91.

Bruzoska, M., Geiger, H., Gauer, S., and Baer, P. (2005). Epithelial differentiation of human adipose tissue-derived adult stem cells. Biochem. Biophys. Res. Commun. 330, 142–150.

Clarke, P. R., and Williams, H. I. (1975). Ossification in extradural fat in Paget’s disease of the spine. Br. J. Surg. 62, 571–572.

Conejero, J. A., Lee, J. A., Parrett, B. M., Terry, M., Wear-Maggitti, K., Grant, R. T., and Breitbart, A. S. (2006). Repair of palatal bone defects using osteogenically differentiated fat-derived stem cells. Plast. Reconstr. Surg. 117, 857–863.

Cousin, B., Andre, M., Arnaud, E., Penicada, L., and Castella, L. (2003). Reconstitution of lethally irradiated mice by cells isolated from adipose tissue. Biochem. Biophys. Res. Commun. 21, 1016–1022.

Vol. 21, June 1, 2010 1785
Josiah, D. T., Zhu, D., Dreher, F., Olson, J., McFadden, G., and Caldas, H. (2010). Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma. Mol. Ther. 18, 377–385.

Kajiyama, H., et al. (2010). Pdx1-transfected adipose tissue-derived stem cells differentiate into insulin-producing cells in vivo and reduce hyperglycemia in diabetic mice. J. Clin. Invest. 120, 469–475.

Kang, S. K., Putnam, L. A., Yontalo, J., Popescu, I. R., Dufour, J., Belousov, A., and Bunnell, B. A. (2004). Neurogenesis of Rhesus adipose stromal cells. J. Cell Sci. 117, 4289–4299.

Kim, J. M., et al. (2007). Systemic transplantation of human adipose stem cells attenuated cerebral inflammation and degeneration in a hemorrhagic stroke model. Brain Res. 1183, 43–50.

Kim, W. S., Park, B. S., Park, S. H., Kim, H. K., and Sung, J. H. (2009). Antivrinkle effect of adipose-derived stem cell: activation of dermal fibroblast by secretory factors. J. Dermatol. Sci. 53, 96–102.

Kingham, P. J., Kalberrmatten, D. F., Mahay, D., Armstrong, S. J., Wiberg, M., and Terenghi, G. (2007). Adipose-derived stem cells differentiate into a Schwann cell phenotype and promote neurite outgrowth in vitro. Exp. Neurol. 207, 267–274.

Kondo, K., Shintani, S., Shiba, R., Murakami, H., Murakami, R., Imaizumi, M., Kitagawa, Y., and Murohara, T. (2009). Implantation of adipose-derived regenerative cells enhances ischemia-induced angiogenesis. Arterioscler. Thromb. Vasc. Biol. 29, 61–66.

Kumai, T., Takakura, Y., Higashiyama, I., and Tamai, S. (1999). Arthroscopic drilling for the treatment of osteochondral lesions of the talus. J. Bone Joint Surg. Am. 81, 1229–1235.

Lee, S. T., et al. (2009). Slowed progression in models of Huntington disease by adipose stem cell transplantation. Ann. Neurol. 66, 671–681.

Lendeckel, S., Jodicke, A., Christophis, P., Heidinger, K., Wulf, J., Fraser, J. K., Hedrick, M. H., Berthold, H., and Howaldt, P. H. (2004). Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic calvarial defects: case report. J. Craniomaxillofac. Surg. 32, 370–373.

Li, K., Han, Q., Yan, X., Liao, D., and Zhao, R. C. (2009). Not a process of simple vicariousness, the differentiation of human adipose-derived mesenchymal stem cells to renal tubal epithelial cells plays an important role in acute kidney injury repairing. Stem Cells Dev. 18, 935–947.

Lin, G., Banie, L., Ning, H., Bella, A. J., Lin, C. S., and Lee, T. F. (2009a). Potential of adipose-derived stem cells for treatment of erectile dysfunction. J. Sex Med. 6 Suppl 3, 320–327.

Lin, G., Wang, G., Banie, L., Ning, H., Shindel, A. W., Fandel, T. M., Lue, T. F., and Lin, C. S. (2010). Treatment of stress urinary incontinence with adipose tissue-derived stem cells. Cytotherapy 12, 88–95.

Lin, G., Wang, G., Liu, G., Yang, J. L., Chang, L. J., Lue, T. F., and Lin, C. S. (2009b). Treatment of type I diabetes with adipose tissue-derived stem cells expressing pancreatic duodenal homeobox 1. Stem Cells Dev. 18, 1399–1406.

Long, J. L., Zik, P., Berke, G. S., and Chiheti, D. K. (2009). Epithelial differentiation of adipose-derived stem cells for laryngeal tissue engineering. Laser biology 120, 125–131.

Mauney, J. R., Nguyen, T., Gillen, K., Kirker-Head, C., Gimble, J. M., and Kaplan, D. L. (2007). Engineering adipose-like tissue in vitro and in vivo utilizing human bone marrow and adipose-derived mesenchymal stem cells with silk fibroin 3D scaffolds. Biomaterials 28, 5280–5290.

Mauro, A. (1961). Satellite cell of skeletal muscle fibers. J. Biophys. Biochem. Cytol. 9, 493–495.

Miranville, A., Heeschen, C., Sengenes, C., Curat, C. A., Busse, R., and Bouloumie, A. (2004). Improvement of postnatal vascularization by human adipose tissue-derived stem cells. Circulation 110, 349–355.

Moss, F. P., and Leblond, C. P. (1971). Satellite cells as the source of nuclei in muscles of growing rats. Anat. Rec. 170, 421–435.

Nakada, A., Fukuda, S., Ichihara, S., Sato, T., Itoi, S., Inada, Y., and Nakamura, T. (2009). Regeneration of central nervous tissue using a collagen scaffold and adipose-derived stromal cells. Cells Tissues Organs 190, 326–335.

Okura, H., Komoda, H., Furimoto, Y., Lee, C. M., Nishida, T., Sawaya, Y., and Matsuayama, A. (2009a). Transdifferentiation of human adipose tissue-derived stromal cells into insulin-producing clusters. J. Artif. Organs 12, 123–130.
Okura, H., Komoda, H., Saga, A., Kakuta-Yamamoto, A., Hamada, Y., Fumimoto, Y., Lee, C. M., Ichinose, A., Sawa, Y., and Matsuyama, A. (2009b). Properties of hepatocyte-like cell clusters derived from human adipose tissue-derived mesenchymal stem cells. Tissue Eng. Part C Methods Epub ahead of print.

Okura, H., et al. (2009c). Cardiomyoblast-like cells differentiated from human adipose tissue-derived mesenchymal stem cells improve left ventricular dysfunction and survival in a rat myocardial infarction model. Tissue Eng. Part C Methods Epub ahead of print.

Park, B. S., Jang, K. A., Sung, J. H., Park, J. S., Kwon, Y. H., Kim, K. J., and Kim, W. S. (2008). Adipose-derived stem cells and their secretory factors as a promising therapy for skin aging. Dermatol. Surg. 34, 1323–1326.

Puisant, B., et al. (2005). Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br. J. Haematol. 129, 118–129.

Reynolds, B. A., and Weiss, S. (1992). Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255, 1707–1710.

Riordan, N. H., et al. (2009). Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J. Transl. Med. 7, 29.

Rodriguez, L. V., Alfonso, Z., Zhang, R., Leung, J., Wu, B., and Ignarro, L. J. (2006). Clonogenic multipotent stem cells in human adipose tissue differentiate into functional smooth muscle cells. Proc. Natl. Acad. Sci. USA 103, 12167–12172.

Ryu, H. H., Lim, J. H., Byeon, Y. E., Park, J. R., Seo, M. S., Lee, Y. W., Kim, W. H., Kang, K. S., and Kweon, O. K. (2009). Functional recovery and neural differentiation after transplantation of allogenic adipose-derived stem cells in a canine model of acute spinal cord injury. J. Vet. Sci. 10, 273–284.

Safford, K. M., Hicok, K. C., Safford, S. D., Halvorsen, Y. D., Wilkison, W. O., Gimble, J. M., and Rice, H. E. (2002). Neurogenic differentiation of murine and human adipose-derived stromal cells. Biochem. Biophys. Res. Commun. 294, 371–379.

Safford, K. M., Safford, S. D., Gimble, J. M., Shetty, A. K., and Rice, H. E. (2004). Characterization of neuronal/glial differentiation of murine adipose-derived adult stromal cells. Exp. Neurol. 187, 319–328.

See, M. J., Suh, S. Y., Bae, Y. C., and Jung, J. S. (2005). Differentiation of human adipose stromal cells into hepatic lineage in vitro and in vivo. Biochem. Biophys. Res. Commun. 328, 258–264.

Shackelford, G. D., Barton, L. L., and McAlister, W. H. (1975). Calcified subcutaneous fat necrosis in infancy. J. Can. Assoc. Radiol. 26, 203–207.

Sun, N., et al. (2009). Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. Proc. Natl. Acad. Sci. USA 106, 15720–15725.

Taxonera, C., Schwartz, D. A., and Garcia-Olmo, D. (2009). Emerging treatments for complex perianal fistula in Crohn’s disease. World J. Gastroenterol. 15, 4263–4272.

Timper, K., Seboek, D., Eberhardt, M., Linscheid, P., Christ-Crain, M., Keller, U., Muller, B., and Zulewski, H. (2006). Human adipose tissue-derived mesenchymal stem cells differentiate into insulin, somatostatin, and glucagon expressing cells. Biochem. Biophys. Res. Commun. 341, 1135–1140.

Trottier, V., Marceau-Fortier, G., Germain, L., Vincent, C., and Fradette, J. (2008). IFATS collection: using human adipose-derived stem/stromal cells for the production of new skin substitutes. Stem Cells 26, 2713–2723.

Uysal, A. C., and Mizuno, H. (2009). Tendon regeneration and repair with adipose derived stem cells. Curr. Stem Cell Res. Ther. Epub ahead of print.

Xu, Y., Liu, L., Li, Y., Zhou, C., Xiong, F., Liu, Z., Gu, R., Hou, X., and Zhang, C. (2008). Myelin-forming ability of Schwann cell-like cells induced from rat adipose-derived stem cells in vitro. Brain Res. 1239, 49–55.

Yamamoto, T., Gotoh, M., Hattori, R., Toriyama, K., Kamei, Y., Iwaguro, H., Matsukawa, Y., and Funahashi, Y. (2009). Periurethral injection of autologous adipose-derived stem cells for the treatment of stress urinary incontinence in patients undergoing radical prostatectomy: report of two initial cases. Int. J. Urol. Epub ahead of print.

Yoon, E., Dhar, S., Chun, D. E., Gharibianian, N. A., and Evans, G. R. (2007). In vivo osteogenic potential of human adipose-derived stem cells/poly lactide-co-glycolic acid constructs for bone regeneration in a rat critical-sized calvarial defect model. Tissue Eng. 13, 619–627.

Zhang, J., et al. (1999). Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes. J. Exp. Med. 189, 1329–1342.

Zuk, P. A., Zhu, M., Ashjian, P., De Ugarte, D. A., Huang, J. L., Mizuno, H., Alfonso, Z. C., Fraser, J. K., Benhaim, P., and Hedrick, M. H. (2002). Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell 13, 4279–4295.

Zuk, P. A., Zhu, M., Mizuno, H., Huang, J., Furlani, J. W., Katz, A. J., Benhaim, P., Lorenz, H. P., and Hedrick, M. H. (2001). Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 7, 211–228.